Yuyu Pharma, a global pharmaceutical company founded in Seoul, South Korea, announced on Wednesday that it has enroled the first patient in a phase two clinical study assessing YP-P10, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties intended to treat patients with dry eye disease (DED).
The company has received approval from the United States Food and Drug Administration (FDA) for its Investigational New Drug Application (IND) for YP-P10 Ophthalmic Solution.
The approval enabled the company to start the phase two clinical study, named ICECAP (randomIzed plaCebo EffiCacy sAfety yP-p10), to assess the safety, tolerability, and efficacy of the product to help advance the treatment of patients with DED. The study is to be carried out in the United States at seven sites with 240 patients. The product has been developed by Yuyu Pharma R&D.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer